Curcumin Attenuates Cuproptosis via Activating Autophagy Through Inhibition of the AKT/mTOR/P70S6K-Signaling Pathway in Parkinson's Disease Models.
Curcumin Attenuates Cuproptosis via Activating Autophagy Through Inhibition of the AKT/mTOR/P70S6K-Signaling Pathway in Parkinson's Disease Models.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Taihe, CN · Author affiliation
Taihe Hospital, Affiliated Hubei University of Medicine, Shiyan, Hubei, China.Location evidence
CN · Author affiliation · country only
School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei, China. jing_zhu0719@163.com.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
This research surveyed the therapeutic potential of curcumin (Cur) in Parkinson's disease (PD), focusing on its effects on cuproptosis and underlying molecular mechanisms. A MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced mouse model and a MPP+ (1-methyl-4-phenylpyridinium)-treated PC12 cell model were used in this study. In vivo, Cur treatment significantly mitigated MPTP-treated dyskinesia and lessened the damage of dopaminergic (DA) neurons in SNpc. Additionally, Cur reversed MPTP-induced changes by increasing TH (tyrosine hydroxylase) expression and decreasing α-syn (α-synuclein) accumulation in the SN. In vitro, Cur mitigated MPP+-treated apoptosis and the cytotoxicity of differentiated PC12 cells. Furthermore, Cur reversed MPTP/MPP+-induced changes in the cuproptosis-related protein expression, including DLAT (dihydrolipoamide S-acetyltransferase), FDX1 (ferredoxin 1), and upregulating SLC31A1 (solute carrier family 31 member 1) and HSP70 (heat shock protein 70). 3-MA (3-methyladenine) reversed Cur-mediated expression levels of DLAT, FDX1, SLC31A1, and HSP70 in the PD models. Mechanistically, Cur decreased the expression of p-AKT (p-protein kinase B), p-mTOR (p-mammalian target of rapamycin), and p-P70S6K (p-70 KDa ribosomal protein S6 kinase) in the PD models, suggesting it has an inhibitory effect on the AKT/mTOR/P70S6K signaling pathway. Furthermore, pretreatment with SC79 (an AKT activator) reversed Cur-induced autophagy activation, supporting the role of this pathway in Cur-mediated neuroprotection. Cur protected against DA neuronal loss by modulating the interplay between cuproptosis and autophagy via the suppression of the AKT/mTOR/P70S6K. The study findings provide novel insights into the mechanism of Cur's neuroprotective effect, highlighting the AKT/mTOR/autophagy/cuproptosis axis as a potential target and Cur as a medicant for PD management.